Cover Image
市場調查報告書

全球預防感染·感染控制市場:感染類型(病原微生物感染,醫療相關感染),醫藥品類型(抗菌藥,抗病毒藥物,抗真菌藥物,疫苗),設備 & 配件,終端用戶,各地區

Infection prevention & Control Market: By Infections (Microbial & Others); By Antimicrobial Drugs (Antibacterial & Others); By Accessories & Equipment (Disinfectants & Others); By End User (Equipment & Drug Usage) & By Geography - (2014-2020)

出版商 IndustryARC 商品編碼 385581
出版日期 內容資訊 英文 180 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球預防感染·感染控制市場:感染類型(病原微生物感染,醫療相關感染),醫藥品類型(抗菌藥,抗病毒藥物,抗真菌藥物,疫苗),設備 & 配件,終端用戶,各地區 Infection prevention & Control Market: By Infections (Microbial & Others); By Antimicrobial Drugs (Antibacterial & Others); By Accessories & Equipment (Disinfectants & Others); By End User (Equipment & Drug Usage) & By Geography - (2014-2020)
出版日期: 2017年08月15日 內容資訊: 英文 180 Pages
簡介

本報告提供全球預防感染·感染控制市場調查,提供市場概要,各感染類型·醫藥品類型·設備 & 配件·終端用戶產業·地區的市場趨勢,市場規模的變化與預測,市場促進·阻礙因素以及課題分析,策略,主要企業的簡介等系統性資訊。

第1章 全球預防感染·感染控制市場:市場概要

第2章 摘要整理

第3章 全球預防感染·感染控制市場:概況

  • 市場佔有率分析
  • 比較分析
    • 產品基準
    • 終端用戶的簡介
    • 專利分析
    • 前五名公司的財務分析

第4章 市場動態

  • 推動市場要素
  • 市場阻礙因素
  • 市場課題
  • 波特的五力分析

第5章 策略分析

  • 價值鏈分析
  • 市場機會分析
  • 產品生命週期分析
  • 價格分析

第6章 全球預防感染·感染控制市場:感染類別

  • 病原微生物感染
  • 醫療相關感染

第7章 全球預防感染·感染控制市場:醫藥品類別

  • 抗菌藥
  • 抗病毒藥物
  • 抗真菌藥物
  • 疫苗

第8章 全球預防感染·感染控制市場:各設備·配件

  • 個人防護裝備
  • 消毒藥
  • 殺菌設備

第9章 全球預防感染·感染控制市場:各終端用戶產業

  • 醫療設備
    • 醫院·診療所
    • 研究所
    • 製造單位
      • 醫藥品
      • 醫療設備
      • 食品·飲料
  • 醫藥品
    • 個人·患者
    • 看護設施

第10章 法規方案

第11章 全球預防感染·感染控制市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第12章 市場熵

  • 新產品的開發
  • M&A,合作,合資企業,聯盟

第13章 企業簡介

  • ABBOTT LABORATORIES
  • ALERE
  • ANSELL LIMITED
  • ASTRAZENECEA
  • BARD (CR) INCORPORATED
  • BECTON, DICKINSON AND COMPANY
  • BELIMED
  • CANTEL
  • COVIDIEN PLC
  • GETINGE GROUP
  • HOLLISTER INCORPORATED
  • JOHNSON & JOHNSON
  • KIMBERLY-CLARK
  • MERCK & CO
  • PFIZER
  • ROCHE
  • SIEMENS AG
  • SUPERMAX CORPORATION
  • Terumo Corporation
  • 3M COMPANY

第14章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Infection prevention and Control (IPC) is a rapidly growing field in the healthcare industry. The proper usage of the IPC products all across the globe has the potential to revolutionize the complete healthcare industry, making it disease free. The market opportunity for IPC is promising, yet conflicting financial Incentives has created uncertainty on how stakeholders can capitalize. The market for Infection prevention is estimated to increase with a CAGR of 5.3% during the forecast period 2015-2020. Infection prevention and control market is experiencing significant growth with the increase in awareness among the people, elderly & aging population, and number of surgeries and proper donning and doffing of Hospital Housekeeper which prevents in the spread of the contagious waste.

Infection prevention and control is the major and significant step in the development and maintenance of products in the Medical Devices, Pharmaceuticals, and food & beverage industries. The adoption of various means of personal protective equipment, disinfection, sterilization and in-house sterilization procedures by hospitals and end users industries has revolutionized the healthcare industry. Sterilization and disinfection protect different products and materials from being contaminated by microbes. The disinfection and sterilization market is going to expand with a CAGR of 6.2% during the period under study. The integration of technologies into traditional healthcare systems is one of the most influencing trends that will drive the growth of this market. The technological advancements will facilitate the availability and implementation of cost-effective technologies across a range of healthcare facilities. The introduction of technically enhanced instruments likes portable autoclaves, In-House & ethylene oxide (EtO) advanced sterilization and so on has resulted in the drastic swing from the previous used equipment's such as steam sterilizer.

The IPC market by anti-microbial drugs in North America in 2014 was valued at $XX billion and is projected to grow at a CAGR of 4.5% during the forecast period. The North American region has been concentrating on relatively easy commercial drugs which were driven by the increase in chronic diseases. This has led to the development of vaccines, since these are specific for a particular infection. The cost of the vaccines varies as per the infected microbes. Thus, followed by anti-bacterial drugs, vaccines show the highest growth rate of 4.8% towards the increasing demand of anti-microbial drugs, where most patients would be managed with a short course of therapy in comparison to the generic antibiotics. According to the World Health Organization, 30.85% of the globally registered hospitals are in the Americas. Moreover, the rapidly aging population in the U.S., Canada and Mexico will drive the need for efficient anti-microbial drugs in hospitals and senior care centres in this region.

The global infection prevention and control market is segmented into bacterial, fungal and viral infections based on the types of microbial infections. In 2014, bacterial infections dominated the market with 44% of the global market share in infection prevention and control market, followed by viral infections, which occupied 39%.

Table of Contents

1. Global Infection Prevention & Control - Market Overview

2. Global Infection Prevention & Control Market - Executive Summary

3. Global Infection Prevention & Control - Market Landscape

  • 3.1. Market share Analysis
  • 3.2. Comparative Analysis
    • 3.2.1. Product Benchmarking
    • 3.2.2. End-User Profiling
    • 3.2.3. Patent Analysis
    • 3.2.4. Top 5 Financial Analysis

4. Global Infection Prevention & Control - Market Forces

  • 4.1. Market Drivers
  • 4.2. Market Constraints
  • 4.3. Market Challenges
  • 4.4. Attractiveness of the Industry
    • 4.4.1. Power of Suppliers
    • 4.4.2. Power of Customers
    • 4.4.3. Threat of New entrants
    • 4.4.4. Threat of Substitution
    • 4.4.5. Degree of Competition

5. Global Infection Prevention & Control Market - Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Opportunity Analysis
  • 5.3. Product Life Cycle Analysis
  • 5.4. Pricing Analysis

6. Global Infection Prevention & Control Market - By Infections

  • 6.1. Microbial Infections
    • 6.1.1. Bacterial Infection
      • 6.1.1.1. Mycobacterium tuberculosis
      • 6.1.1.2. Clostridium Difficile
      • 6.1.1.3. E. Coli
      • 6.1.1.4. Helicobacter pylori
      • 6.1.1.5. Salmonella
      • 6.1.1.6. Others
    • 6.1.2. Viral Infection
      • 6.1.2.1. Ebola Virus
      • 6.1.2.2. Human Immunodeficiency Virus (HIV)
      • 6.1.2.3. Herpes Simplex Virus
      • 6.1.2.4. Yellow Fever
      • 6.1.2.5. Dengue Viruses
      • 6.1.2.6. Others
    • 6.1.3. Fungal Infection
      • 6.1.3.1. Cryptococcus gattii
      • 6.1.3.2. Aspergillis
      • 6.1.3.3. PCP: Pneumocystis Pneumonia
      • 6.1.3.4. Fungal Keratitis
      • 6.1.3.5. Dermatophytes
      • 6.1.3.6. Others
  • 6.2. Healthcare Associated Infection
    • 6.2.1. Hospital Acquired Infection
      • 6.2.1.1. Central Line-associated Bloodstream Infection (CLABSI)
      • 6.2.1.2. Catheter-associated Urinary Tract Infection
      • 6.2.1.3. Surgical Site Infection
      • 6.2.1.4. Ventilator-associated Pneumonia (VAP) Infection
    • 6.2.2. Community acquired Infection
      • 6.2.2.1. Methicillin-resistant Staphylococcus aureus (MRSA) infection
      • 6.2.2.2. Community-acquired pneumonia

7. Global Infection Prevention & Control Market - By Anti-Microbial Drugs

  • 7.1. Anti- Bacterial Drugs
  • 7.2. Anti- Viral Drugs
  • 7.3. Anti-fungal Drugs
  • 7.4. Vaccines

8. Infection Prevention & Control Market - By Accessories and Equipment

  • 8.1. Personal Protective Equipment
    • 8.1.1. Gloves
    • 8.1.2. Surgical Masks & Respirators
    • 8.1.3. Surgical Drapes & Gown
    • 8.1.4. Surgical Foot Covers
    • 8.1.5. Medical Safety Glasses
    • 8.1.6. Others
  • 8.2. Disinfectants
    • 8.2.1. Hand Sanitizers
    • 8.2.2. Disinfectant Wipes
    • 8.2.3. Surface Disinfectants
    • 8.2.4. Instrument Disinfectants
    • 8.2.5. Surgical Disinfectants
    • 8.2.6. Environmental Disinfectants
    • 8.2.7. Others
  • 8.3. Sterilization
    • 8.3.1. Medical Device Sterilization Equipment
      • 8.3.1.1. Wet/ Steam Sterilization (Autoclave)
      • 8.3.1.1.1. Vertical Autoclave
      • 8.3.1.1.2. Horizontal Autoclave
      • 8.3.1.1.3. Portable Autoclave
      • 8.3.1.2. Dry Heat Sterilization
      • 8.3.1.3. Low Temperature Sterilization
      • 8.3.1.3.1. In-House Steam Sterilization
      • 8.3.1.3.2. Ethylene Oxide (EO) Sterilization
      • 8.3.1.3.3. Gamma and eBeam Sterilization

9. Global Infection Prevention & Control Market - By End User Industry

  • 9.1. End Users: By Equipment Usage
    • 9.1.1. Hospitals & Clinics
    • 9.1.2. Medical laboratories
    • 9.1.3. Manufacturing Units
      • 9.1.3.1. Pharmaceuticals
      • 9.1.3.2. Medical Devices
      • 9.1.3.3. Food & Beverages Industry
  • 9.2. End Users: By Drug Usage
    • 9.2.1. Individuals & Patients
    • 9.2.2. Nursing & Senior care Centers

10. Global Infection Prevention & Control Market - Regulatory Scenario

11. Global Infection Prevention & Control Market - Geographic Analysis

  • 11.1. Introduction
  • 11.2. North America
    • 11.2.1. US
    • 11.2.2. Canada
    • 11.2.3. Mexico
    • 11.2.4. Others
  • 11.3. Europe
    • 11.3.1. France
    • 11.3.2. Germany
    • 11.3.3. Italy
    • 11.3.4. Spain
    • 11.3.5. UK
    • 11.3.6. Others
  • 11.4. APAC
    • 11.4.1. China
    • 11.4.2. India
    • 11.4.3. Japan
    • 11.4.4. Korea
    • 11.4.5. Others
  • 11.5. ROW
    • 11.5.1. Saudi Arabia
    • 11.5.2. South Africa
    • 11.5.3. Brazil
    • 11.5.4. Russia
    • 11.5.5. Others

12. Market Entropy

  • 12.1. New Product Launches
  • 12.2. M&As, Collaborations, JVs and Partnerships

13. Company Profiles (Overview, Financials, SWOT Analysis - Top 5 Companies, Developments, Product Portfolios)

  • 13.1. ABBOTT LABORATORIES (ABBOTT DIACNOSTICS)
  • 13.2. ALERE
  • 13.3. ANSELL LIMITED
  • 13.4. ASTRAZENECEA
  • 13.5. BARD (CR) INCORPORATED
  • 13.6. BECTON, DICKINSON AND COMPANY
  • 13.7. BELIMED
  • 13.8. CANTEL
  • 13.9. COVIDIEN PLC
  • 13.10. GETINGE GROUP
  • 13.11. HOLLISTER INCORPORATED
  • 13.12. JOHNSON & JOHNSON
  • 13.13. KIMBERLY-CLARK
  • 13.14. MERCK & CO
  • 13.15. PFIZER
  • 13.16. ROCHE
  • 13.17. SIEMENS AG
  • 13.18. SUPERMAX CORPORATION
  • 13.19. TERUMO CORPORATION
  • 13.20. 3M COMPANY

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

14. Appendix

  • 14.1. Abbreviations
  • 14.2. Sources
  • 14.3. Research Methodology
  • 14.4. Bibliography
  • 14.5. Compilation of Expert Insights
  • 14.6. Disclaimer
Back to Top